529.90 CHF -10.70 -1.98%
03:19:25 AM BATS Europe
Plus500. 82% of retail CFD accounts lose money


Lonza Stock Snapshot

45.21 B
Market Cap in USD
68.84 M
Number of Shares
4.00
Dividend in CHF
1.13
Dividend Yield
39.82
P/E Ratio
96.96
Free Float in %
8.88
EPS in CHF
131.07
Book Value per Share in CHF
19.26
Cash Flow per Share in CHF

Historical Prices for Lonza

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Lonza Analyst Opinions

Date Analyst Rating Price

Lonza Estimates* in CHF

  2024 2025 2026 2027 2028
Revenue 6,676 7,818 8,726 9,856 11,030
Dividend 4.57 5.36 6.34 8.53 9.89
Dividend Yield (in %) 0.82 % 0.97 % 1.14 % 1.54 % 1.78 %
EPS 13.66 16.63 20.11 24.41 29.72
P/E Ratio 40.60 33.35 27.57 22.72 18.66
EBIT 1,271 1,528 1,818 2,189 2,670
EBITDA 1,871 2,245 2,613 3,018 3,762
Net Profit 878 1,122 1,368 1,659 2,030
Net Profit Adjusted 961 1,165 1,403 1,694 2,088
Pre-Tax Profit 1,092 1,378 1,661 2,044 2,472
Pre-Tax Profit Reported 992 1,337 1,636 1,915 2,462
EPS (Non-GAAP) ex. SOE - - - - -
EPS (GAAP) 11.79 15.38 18.60 23.33 29.12
Gross Income 2,399 2,832 3,236 3,572 4,119
Cash Flow from Investing -2,419 -1,592 -1,623 -1,738 -1,858
Cash Flow from Operations 1,483 1,634 2,043 2,377 2,825
Cash Flow from Financing 128 -236 -342 -582 -825
Cash Flow per Share 21.26 25.39 30.65 33.60 43.20
Free Cash Flow -151 95 371 777 1,057
Free Cash Flow per Share -2.37 -1.13 2.82 5.69 14.93
Book Value per Share 133.49 143.10 156.09 164.26 175.47
Net Debt 3,111 3,683 3,720 3,975 4,654
Research & Development Exp. 93 102 107 106 174
Capital Expenditure 1,668 1,649 1,665 1,651 1,816
Selling, General & Admin. Exp. 1,018 1,085 1,137 949 977
Shareholder’s Equity 9,411 10,033 10,922 11,636 12,654
Total Assets 17,919 18,982 20,171 21,458 22,350
  Previous Quarter
ending 06/30/24
Current Quarter
ending 09/30/24
Next Quarter
ending 12/31/24
Current Year
ending 12/31/24
Next Year
ending 12/31/25
Earnings Estimates
No. of Analysts - - - 23 23
Average Estimate - - - 13.657 CHF 16.625 CHF
Year Ago - - - 8.882 CHF -
Publish Date - - - - -
Revenue Estimates
No. of Analysts - - - 23 23
Average Estimate - - - 6,676 CHF 7,818 CHF
Year Ago - - - 6,717 CHF -
Publish Date - - - - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. CHF

2023 2022 2021 2020 2019 2018 2017
Sales 6,717.00 6,223.00 5,409.00 4,508.00 5,920.00 5,542.00 5,105.00
Change of sales in % 7.94 15.05 19.99 -23.85 6.82 8.56 23.55
Gross profit on sales 1,816.00 2,300.00 1,969.00 1,706.00 2,172.00 2,018.00 1,775.00
Gross profit on sales change in % -21.04 16.81 15.42 -21.45 7.63 13.69 24.30
Operating income 854.00 1,349.00 819.00 937.00 1,032.00 946.00 744.00
Operating income change in % -36.69 64.71 -12.59 -9.21 9.09 27.15 36.26
Income before tax 803.00 1,446.00 788.00 789.00 848.00 805.00 578.00
Income before tax change in % -44.47 83.50 -0.13 -6.96 5.34 39.27 54.55
Income after tax 654.00 1,215.00 2,944.00 869.00 756.00 559.00 726.00
Income after tax change in % -46.17 -58.73 238.78 14.95 35.24 -23.00 141.20

Balance Sheet in Mio. CHF

2023 2022 2021 2020 2019 2018 2017
Total liabilities 7,571.00 6,892.00 6,868.00 7,741.00 7,276.00 7,631.00 7,987.00
Long-term liabilities per share 66.67 51.32 60.63 62.52 61.93 70.72 78.31
Equity 9,512.00 10,665.00 9,823.00 6,884.00 6,565.00 6,290.00 6,253.00
Equity change in % -10.80 8.69 43.07 4.94 4.44 0.21 163.48
Balance sheet total 17,083.00 17,557.00 16,691.00 14,625.00 13,841.00 13,921.00 14,240.00
Balance sheet total change in % -2.70 5.19 14.13 5.66 -0.57 -2.24 98.69

Key Data in CHF

2023 2022 2021 2020 2019 2018 2017
Sales per share 91.16 83.69 72.61 60.34 79.39 74.17 74.57
P/E ratio (year end quote, basic EPS) 39.82 27.68 19.21 48.70 34.62 33.90 24.61
P/E ratio (year end quote, diluted EPS) 39.85 27.73 19.27 48.90 34.84 34.05 24.84
P/E ratio (year end quote) 39.82 27.68 19.21 48.70 34.62 33.90 24.61
Dividend yield in % 1.13 0.77 0.39 0.53 0.78 1.08 1.04
Equity ratio in % 55.33 60.36 58.41 46.60 46.92 44.67 43.57
Debt ratio in % 44.32 39.25 41.15 52.93 52.57 54.82 56.09

Lonza Dividend Calendar

Date Name Dividend *yield Currency
2023 Lonza AG (N) 4.00 1.13 CHF
2022 Lonza AG (N) 3.50 0.77 CHF
2021 Lonza AG (N) 3.00 0.39 CHF
2020 Lonza AG (N) 3.00 0.53 CHF
2019 Lonza AG (N) 2.75 0.78 CHF
2018 Lonza AG (N) 2.75 1.08 CHF
2017 Lonza AG (N) 2.75 1.04 CHF
2016 Lonza AG (N) 2.55 1.56 CHF
2015 Lonza AG (N) 2.32 1.53 CHF
2014 Lonza AG (N) 2.32 2.23 CHF
2013 Lonza AG (N) 1.99 2.54 CHF
2012 Lonza AG (N) 1.99 4.36 CHF
2011 Lonza AG (N) 1.99 3.87 CHF
2010 Lonza AG (N) 1.99 2.87 CHF
2009 Lonza AG (N) 1.62 2.40 CHF
2008 Lonza AG (N) 1.75 1.79 CHF
2007 Lonza AG (N) 1.75 1.27 CHF
2006 Lonza AG (N) 1.50 1.42 CHF
2005 Lonza AG (N) 1.30 1.62 CHF
2004 Lonza AG (N) 1.30 2.03 CHF
2003 Lonza AG (N) 1.30 1.83 CHF
2002 Lonza AG (N) 1.90 2.26 CHF
2001 Lonza AG (N) 19.00 1.75 CHF
2000 Lonza AG (N) 15.00 1.59 CHF
*Yield of the Respective Date

Lonza Calendar

Event Estimate Info Date
Earnings Report - Q4 2024 Earnings Release 01/25/2025
Earnings Report - Q2 2025 Earnings Release 07/24/2025
Earnings Report - Q4 2025 Earnings Release 01/28/2026
Earnings Report - Q2 2026 Earnings Release 07/23/2026
Earnings Report - Q4 2026 Earnings Release 01/27/2027

Lonza Past Events

Event Actual EPS Info Date
Earnings Report - Q2 2024 Earnings Release 07/25/2024

Lonza Profile

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
2
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Lonza Shareholder

Owner in %
Freefloat 96.96
Lonza Group AG 2.99
Government Pension Fund - Global (The) 2.81
Vanguard Total International Stock Index Fund 1.39
Vanguard Developed Markets Index Fund 0.85
Harding Loevner International Equity Portfolio 0.69
Vanguard Institutional Total Intl. Stock Market Index Tr. II 0.69
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Lonza Management

Name Job
R. Jean-Marc Sidney Huët Chairman
Wolfgang Wienand Chief Executive Officer
Philippe Deecke Chief Financial Officer
Ulrike Käppler Chief Human Resources Officer
Maria Soler Nunez Head-Group Operations
Barbara May Richmond Independent Director
Jürgen B. Steinemann Independent Director
Marion Helmes Independent Director
Roger Nitsch Independent Director
Olivier Verscheure Independent Director
Angelica Kohlmann Independent Director
Lyle Wheeler Investor Relations Contact
Christoph Mäder Vice Chairman